GAITHERSBURG, MD – October 28, 2025 – Anthony Saleh (CEO) will present miRecule at the upcoming MACC Conference in Philadelphia on Thursday, October 30 at 12:10 PM, as part of the Healthcare-Biotech track companies presenting at the conference.
GAITHERSBURG, MD – October 9, 2025 – miRecule, Inc. today announced that Dr. Hunter Wallace will present data from its collaboration with Sanofi at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Budapest, Hungary. The presentation will...
GAITHERSBURG, MD – October 1, 2024 – miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled...
Chicago, May 2024 — miRecule, a cutting-edge startup focused on developing antibody RNA conjugate therapeutics, clinched the top spot at the prestigious MedCity INVEST Biopharma track competition held at the Ritz Carlton in Chicago. The event, presented by MedCity...
miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the...
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400...
